Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

@article{Bevan2014DiseaseAF,
  title={Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?},
  author={Carolyn J. Bevan and Bruce A. C. Cree},
  journal={JAMA neurology},
  year={2014},
  volume={71 3},
  pages={269-70}
}
Since the introduction of interferon beta-1b in 1993, the number of disease-modifying therapies for multiple sclerosis (MS) has grown at a remarkable pace. Currently there are 10 treatments approved by the US Food and Drug Administration, each with varying effects on important clinical and radiographic markers of disease activity. Multiple sclerosis is one of many immunemediated diseases in which significant advancements in disease modification have been made. Tumor necrosis factor inhibitors… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 22 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: findings from the DEFINE study

  • G Giovannoni, R Gold, L Kappos
  • J Neurol. 2012;259:S106-S106
  • 2012

Similar Papers

Loading similar papers…